O ne of the earliest events in atherogenesis in cholesterol-fed animals is an increased binding of monocytes to endothelial cells and their entry into the vessel wall. 1 •* These findings suggest that lipoproteins may play a role in the altered binding of monocytes to the endothelial cell surface. In previous studies, we demonstrated that treatment of endothelial cells with /3-migrating very low density lipoprotein (/3-VLDL) and malondialdehydealtered low density lipoprotein (MDA-LDL), but not LDL, increased the production of a monocyte chemotactic factor that may modulate monocyte migration into the vessel wall. 3 The present study was undertaken to evaluate the effect of /3-VLDL and LDL on the ability of endothelial cells to bind monocytes. The characteristics of binding were examined, and the effect of antibodies to monocyte surface antigens on the adhesion was determined.
Methods Upoprotelns
LDL was prepared from normal human plasma (d=1.019 to 1.063), and 0-VLDL was prepared from d<1.006fractions of cholesterol-fed rabbit plasma as previously described.
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Endothelial Cells
Human umbilical vein endothelial (HUV) cells from passages 2 to 4 were cultured in Medium 199 containing 15% calf serum (CS). Rabbit aorta endothelial cells (RAEC) from passages 9 to 14 were cultured in Medium 199 containing 15% CS as previously described. 6 - 8 Human aortic endothelial cells isolated as described previously were obtained from Mamad Navab. 10 The cells were cultured to confluence in 24-or 48-well tissue culture plates. The cells were then transferred to the control media (Dulbecco's modified Eagle's medium, DME, or Media 199+5% CS) or to media (DME or Media 199+5% CS) containing /3-VLDL (50 to 100 jig/ml), or LDL (100 MQ/ml) for 48 hours or for other designated time periods before the adhesion assays were performed. These conditions were nontoxic to the cells. Exposure of the cells to /3-VLDL effectively induced cholesterol loading with a 60% to 80% increase in cellular cholesterol content. There was no statistically significant increment in the cholesterol content of the LDL-treated cells. To expose the monolayers to endotoxin (LPS), 5 ng/ml of LPS was added to the wells, which were then incubated for 4 hours before the adhesion assays.
Leukocytes
Human peripheral blood monocytes (MO) were obtained from heparinized blood by elutriation 11 or by the method described by Fogelman et al. 12 The human monocyte cell line, THP-1 (ATCC TIB-202), was also used as a source of monocytes in some studies. Human neutrophils (PMN) were isolated on Ficoll-Hypaque followed by dextran sedimentation. 13 Leukocytes were washed and resuspended at a concentration of 6x10* cells/ml in RPMI media containing 1 % fetal catf serum (FCS) before performing the adhesion assays. In studies with leukocyte antibodies, smaller volumes were used, and direct counting of adherent leukocytes was utilized to assess adhesion. These assays were performed in 48-well dishes by adding 2x10 s monocytes per well to the confluent endothelial monolayers and then incubating at 37°C for 1 hour. After rinsing off the nonadherent leukocytes, the endothelial monolayers with adherent leukocytes were fixed in 1 % fresh glutaraldehyde in PBS. The adherent leukocytes were then counted microscopically in 20 fields at 200x with a microgrid. The average number of leukocytes adhering per millimeter squared of endothelial monolayer was determined and compared to the number of leukocytes In the initial inoculum to calculate the percent adhesion.
MONOCYTE ADHESION TO 0-VLDL ENDOTHELIUM
Antibody Studies
The leukocyte antibodies Leu M3, to the Mo2 monocyte antigen, (Becton-Dickinson, Mountain View, CA), and TS1/22, to the alpha chain of the leukocyte functionassociated-antigen-1 (LFA), 15 were employed. The antibody was incubated with 10 6 leukocytes at room temperature for 15 minutes. For Leu M3, 0.5 jig/ml and for TS1/22, a 1:250 dilution of ascites fluid were used. These concentrations were determined to be saturating by using a peroxidase-labeled second antibody. This suspension was then diluted with media (DME+1% FCS for RAEC, Media 199+1% FCS for HUV assays), and 0.5 ml (containing 2x10* leukocytes) was added to the endothelial monolayers to determine adhesion as described above for the microscopic counting method.
Results
Untreated RAEC bound 15%±8% of peripheral blood monocytes and 13%±4% of TUP cells in these preparations after 1 hour of incubation at 25°C. Binding to HUV cells was greater, with 26% ±13% of peripheral blood monocytes and 23%±9% of THP cells adhering. Since we saw no differences between peripheral blood monocytes and THP cells, the results are combined, and they are referred to as monocytes. Monocyte adhesion increased with the time of incubation of the monocytes with the endothelial cells during the first 60 minutes and then leveled off (Figure 1 ). Adhesion increased with increasing concentrations of 0-VLDL up to 50 /xg/ml and then leveled off ( Figure 2 ). Concentrations of 50 to 100 /xg/ml were used as standard treatments in all subsequent assays. The treatment of RAEC with 0-VLDL resulted in a 1.5-to 6.8-fold increase in the number of adherent monocytes, with an average of 34%±12% of the monocytes adhering to the /3-VLDL-treated cells (p<0.001). Treatment of HUV with /3-VLDL also resulted in an increase in monocyte binding, with 40%±20% of monocytes bound. However, since the baseline adhesion to untreated HUV cells was higher (26.7%) in these studies, this resulted in only a 1.2-to 2.5-fold increase in binding ( Figure 3 ). For human aortic cells, a similar twofold increase in binding was observed (untreated 12%±3%, /3-VLDL 24%±2%). Treatment with LDL in these conditions induced a modest, but not statistically significant, increase in monocyte adhesion to RAEC cells (15%±7% to untreated monolayers, 21 % ± 12% to LDL-treated monolayers) and no change in monocyte adhesion to HUV (22%±10% to untreated monolayers, 23%±5% to LDL treated monolayers).
The ability of endothelial cells to bind monocytes varied with the time of exposure of the endothelium to the 0-VLDL. There was an initial increase in adhesion seen after a 6-hour period of exposure and a continued rise after 24 hours of exposure to lipoproteins (Figure 4) . Neutrophils did not show a similar augmentation of adhesion to 0-VLDL-treated endothelial cells. There were 8%±5% neutrophils adherent to untreated endothelial cells vs. 10%±5% to 0-VLDL-treated cells ( Figure 5 ). Neutrophils did, however, demonstrate an increased adhesion when LPS was used to treat the endothelial cells, as has been previously reported by Schleimer and RutJedge. 16 Monocytes also showed an increased adhesion to LPStreated endothelial cells, which was slightly higher than that seen when 0-VLDL was used to treat the endothelial monolayers ( Figure 5 ).
Since the effects of LPS and /3-VLDL on binding were different, it seemed unlikely that LPS contaminating the 0-VLDL preparations could be responsible for the observed effects. Nonetheless, several experiments were conducted to rule out any LPS contamination of the preparations. Using Western blotting (detection level, 5 ng) we found no detectable LPS in 300 HQ of our /3-VLDL preparations. This was well below the level for significant activity of LPS bound to LDL or 0-VLDL (25 to 50) ng/ml on the production of endothelial-derived chemotactic factor, 17 and below the level of LPS bound to LDL or /3-VLDL, which we have found to be necessary to effect monocyte binding to the endothelium (100 ng/ml) (data not shown). The presence of free LPS in the preparations was ruled out when we found activity in /3-VLDL preparations refloated at a density of <1.006. Under such conditions, free LPS does not come to the top of the tube. 18 The effect of the antibody to LFA and the Mo2 determinant (anti-Leu-M3) on the binding of monocytes and neutrophils was examined ( Figure 6 ). Antibody treatment did not after the baseline adhesion of monocytes or neutrophils to the untreated endothelial cells in our system. Anti-LFA inhibited LPS, and 0-VLDL induced mono- cyte adhesion by about 25% and inhibited LPS-induced neutrophil binding by 50% to 60%. Anti-LFA antibody similarly inhibited adhesion of TUP to the endothelium. Antj-Leu-M3 blocked only monocyte binding, inhibiting approximately 25% of the binding after /3-VLDL or LPS treatment. Neither antibody completely blocked the augmented adhesion of the leukocytes to /3-VLDL or to LPS-treated cells.
Discussion
An increased monocyte adhesion to the endothelium is an early finding in atherosclerosis and other inflammatory reactions. The mechanisms involved in this increased adhesion could relate to alterations in monocytes, endothelial cells, or plasma components. Previous studies have shown that postprandial (PP) LDL and PP VLDL that are incubated with endothelial monolayers induced monocyte adhesion if the lipoprotein was present during the adhesion incubation. 1920 The effect was reduced if PP LDL was removed before the addition of the monocytes. In those studies, it was not clear if PP LDL was working on the endothelium or on the monocyte, or if it was itself an adhesion factor. In our studies, the role of /3-VLDL itself as the binding molecule seems unlikely because we observed increased binding of monocytes only when cells were treated for more than 4 hours with /3-VLDL. Furthermore, the /3-VLDL was rinsed from the wells before the addition of the monocytes; thus the increased adhesion that we observed appears to be related to alterations induced by the /3-VLDL in the endothelial monolayer itself. In this regard, it is noteworthy that using similar incubation conditions, we previously demonstrated that 0-VLDL can induce endothelial cells to produce increased quantities of monocyte-specrfic, endothelial cell-derived, chemotactic factor, 3 suggesting that 0-VLDL may be an activator of multiple endothelial cell functions and monocyte endothelial cell interactions. The fact that increased adhesion after /3-VLDL treatment was seen in both the homologous system (human monocytes on human endothelial cells) and the heterologous system (human monocytes on rabbit endothelial cells) suggests a common mechanism in the two species. The increased adhesion induced by /3-VLDL on the endothelium was specific for monocytes, with no alteration in neutrophil adhesion being observed. In contrast, LPS induced a significant augmentation of neutrophil as well as monocyte adhesion. These findings indicate that the type of leukocyte adhering to the endothelium during inflammatory reactions can be determined by the nature of the stimulus to the endothelium.
The family of proteins known as leukocyte adhesion molecules plays a major role in the adhesion of leukocytes to the endothelium. 1621 They are designated the CD18 complex and consist of a common beta chain and a variable alpha chain. These molecules have been found to be important in a variety of functions in neutrophils and lymphocytes and also to some degree in monocytes. Previous studies have shown that some monoclonal antibodies to CD18 block granulocyte adhesion to the endothelium 22 ' 23 ' 24 ; however, not all monoclonal antibodies are equally effective in blocking the adhesiondependent functions of granulocytes. 28 In general, monoclonal antibodies to the common beta chain were less effective in blocking monocyte than neutrophil adhesion. 26 Our studies looked at one of the CD18 family, LFA. Antibodies to the alpha chain of LFA partially inhibited the augmented monocyte adhesion induced by /3-VLDL. The effects of antibody to the other subunits of the CD18 complex have not been assessed. Antibodies to Mo2, another monocyte antigen, however, resulted in similar inhibition of monocyte adhesion to /3-VLDL-treated endothelial cells. The exact function of the Mo2 antigen has not been defined; however, it is a cell surface glycoprotein found only on monocytes, and it is connected to an inositol phosphate-linked pathway. 27 -2829 The present study suggests that Mo2 may have a role in monocyte adhesion. These inhibitor studies suggest that: 1) determinants other than the CD18 complex are important in monocyte binding induced by /3-VLDL and by LPS, 2) Mo2 may be one of these determinants, and 3) some of the determinants induced by LPS for monocyte binding are similar to those induced by 0-VLDL.
The precise mechanisms of the increased monocyte adhesion induced by /3-VLDL on endothelial cells is at this time unclear. Further studies will be necessary to determine if these mechanisms relate to general surface membrane or antigenic changes, to the production or release of an adhesion factor, or to alternate mechanisms. We can, however, conclude that lipoprotein does induce a significant alteration in monocyte-endothelial binding and propose that the monocytic nature of the early arteriosclerotic reaction may be determined by the interaction of lipoproteins with the endothelium. perform antibody inhibition studies and for supplying us with the anti-LFA antibody and Mamad Navab for providing human aorta endothelial cells.
